Allogene Therapeutics ALLO
NASDAQ ALLO
$1.60 0.00 (-0.31%)
As of: Oct 1, 2026 · 2:57 PM EDT

Allogene Therapeutics (ALLO) Liabilities and Shareholders Equity (2018 - 2026)

Updated

Allogene Therapeutics' Liabilities and Shareholders Equity was $550.09 million in Q2 2026, up 16.9% from $470.59 million a year earlier and up 38.9% from the prior quarter.

Analysis

Allogene Therapeutics (ALLO) Liabilities and Shareholders Equity (2018 - 2026) Analysis & Trends

At the end of FY2025, Liabilities and Shareholders Equity at Allogene Therapeutics came in at $415.91 million, down 24.2% from FY2024.

  • Liabilities and Shareholders Equity has now declined for five consecutive years, with a five-year compound annual growth rate of -19.5% (FY2020 to FY2025).
  • In earlier years, Liabilities and Shareholders Equity was $548.71 million in FY2024 (-14.6%), $642.84 million in FY2023 (-21.8%), $821.58 million in FY2022 (-21.8%) and $1.05 billion in FY2021 (-14.4%).
  • The Q2 2026 figure marks the highest quarterly Liabilities and Shareholders Equity since Q3 2024.
  • Compared with a year earlier, Liabilities and Shareholders Equity was higher in 1 of the last eight quarters, with an average decline of 15.9%.
  • The best year-over-year quarter for Liabilities and Shareholders Equity over five years was Q2 2026 (growth of 16.9%); the worst was Q2 2025 (a decline of 27.3%).
  • Per Business Quant data, ALLO's Liabilities and Shareholders Equity in the three quarters before Q2 2026 was $395.96 million (Q1 2026), $415.91 million (Q4 2025) and $439.77 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 Allogene Therapeutics 552.55 Mn 552.55 Mn - 550.09 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 550.09 Mn
Mar 31, 2026 395.96 Mn
Dec 31, 2025 415.91 Mn
Sep 30, 2025 439.77 Mn
Jun 30, 2025 470.59 Mn
Mar 31, 2025 507.98 Mn
Dec 31, 2024 548.71 Mn
Sep 30, 2024 589.12 Mn
Jun 30, 2024 646.88 Mn
Mar 31, 2024 586.35 Mn
Dec 31, 2023 642.84 Mn
Sep 30, 2023 713.41 Mn
Jun 30, 2023 773.01 Mn
Mar 31, 2023 750.13 Mn
Dec 31, 2022 821.58 Mn
Sep 30, 2022 894.48 Mn
Jun 30, 2022 955.62 Mn
Mar 31, 2022 978.09 Mn
Dec 31, 2021 1.05 Bn
Sep 30, 2021 1.08 Bn
API Access

Allogene Therapeutics Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=ALLO&period=max&api_key=YOUR_API_KEY